Four out of 20 patients in the thalidomide group ( 20 % ) vs four out of 19 patients in the placebo group ( 21 % ) had a partial cutaneous response at month 3 ( difference in proportion of -1 % [ 95 % CI , -26 % to +24 % ] for thalidomide vs placebo , P = 1.0 ) .